Ligand Pharma stock analysis
Ligand Pharma (LGDN) Stock Price & Analysis
LGDN Stock Chart & Stats
- Day’s Range
- EUR 274.00 - EUR 274.00
- 52-Week Range
- EUR 151.00 - EUR 288.00
- Previous Close
- EUR 262.00
- Volume
- N/A
- Average Volume (3M)
- 1
- Market Cap
- EUR 5.63B
- Enterprise Value
- EUR 6.94B
- Total Cash (Recent Filing)
- EUR 447.39M
- Total Debt (Recent Filing)
- EUR 1.15B
- Price to Earnings (P/E)
- 121.3
- Beta
- 0.42
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 2.58
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Royalty Revenue Growth
Strong royalty growth demonstrates that Ligand’s partnered-asset model is gaining commercial traction. Because royalties can scale with partner product sales without requiring a large direct sales force, continued portfolio performance could support recurring revenue and operating leverage over the next several quarters.
Diversified Royalty Portfolio
A broad portfolio spreads Ligand’s economic exposure across many partnered programs and development stages, reducing reliance on any single asset. The scale also creates multiple opportunities for future approvals, launches, milestones and royalty growth to replenish or expand the revenue base.
Cash Generation
Current cash generation provides internal funding for royalty investments and corporate needs while indicating that reported earnings are substantially supported by cash. This strengthens Ligand’s ability to compound its portfolio without relying entirely on external financing, despite historical variability.
Bears Say
Declining And Volatile Revenue
The recent topline decline and uneven multi-year profitability indicate that Ligand’s earnings base is not yet consistently durable. Revenue can be affected by licensing events, milestones and partner product performance, making forward earnings less predictable even while current margins remain positive.
Higher Leverage
The higher debt burden increases balance-sheet risk and leaves Ligand with less flexibility than in prior years to absorb setbacks or fund new opportunities. Greater leverage can also constrain capital allocation if cash flows weaken or portfolio investments require additional funding.
Clinical And Regulatory Binary Risk
Ligand’s royalty and milestone model depends on partner-led clinical and regulatory progress, so failed studies or delayed decisions can reduce expected future cash flows. This risk is structural to the biotechnology portfolio and remains relevant across multiple upcoming catalysts.
LGDN FAQ
What was Ligand Pharma’s price range in the past 12 months?
What is Ligand Pharma’s market cap?
When is Ligand Pharma’s upcoming earnings report date?
How were Ligand Pharma’s earnings last quarter?
Is Ligand Pharma overvalued?
Does Ligand Pharma pay dividends?
What is Ligand Pharma’s EPS estimate?
How many shares outstanding does Ligand Pharma have?
What happened to Ligand Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ligand Pharma?
What is the TipRanks Smart Score and how is it calculated?
Ligand Pharma Stock Smart Score
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Todd C. Davis
- Employees
- 47
- Website
- www.ligand.com
- Address
- 555 Heritage Drive, Jupiter, FL, 33458, US
Ligand Pharma (LGDN) Earnings & Revenues
LGDN Company Deck
LGDN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Royalty revenue grew 51%, adjusted EPS guidance was raised, the XOMA acquisition expanded the commercial and pipeline portfolio, deployable capital remained substantial, and management highlighted multiple upcoming catalysts. Offsetting items included lower reported adjusted EPS versus a prior period with one-time income, a GAAP net loss, higher one-time G&A costs, cash usage for the XOMA acquisition, revenue-timing uncertainty and clinical development risk.
View all DE:LGDN earnings summariesLGDN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 7 |
| Technical Analysis | 3 | 5 | 1 |
| Moving Averages | 6 | 0 | 6 |
